FLUNIXIN TECNOFARM

FLUNIXIN TECNOFARM

FLUNIXIN TECNOFARM

DESCRIPTION
Anti-inflammatory, analgesic and antipyretic non-narcotic and non-steroidal, based on Flunixin Meglumine in injectable solution.

FLUNIXIN TECNOFARM

COMPOSITION

Flunixin, Meglumine: 5 g.
Excipients csp: 100 ml.

ACTION
Flunixin is a potent non-narcotic analgesic with anti-inflammatory and antipyretic activity. In Veterinary Medicine, it is associated with meglumine, which acts as a solubilizing agent. 
It is used for the relief of inflammation and pain associated with musculoskeletal system disorders and colic of horses and other conditions in pigs and cattle. 
It has a strong inhibitory action of the cyclo-oxygenase system of the inflammatory reaction, which prevents the formation of prostaglandins and thromboxanes from Arachidonic acid.

INDICATIONS
Antiinflammatory, analgesic and antipyretic non-narcotic and non-steroidal. 
Horses: muscle, bone and / or joint inflammations: trauma, rachialgia, myalgias, arthropathies, myositis, bursitis, tendonitis. Treatment of colic and infectious or non-infectious neonatal diarrhea. Respiratory pathologies. Treatment of endotoxic shock. 
Cattle: Coliform mastitis, metritis, intestinal and respiratory pathologies, febrile processes in general, musculoskeletal disorders. Treatment of endotoxic shock. 
Porcine: Supportive therapy in the syndrome metritis-mastitis-agalaxia and gastro intestinal pathologies. Treatment of endotoxic shock.

CONTRAINDICATIONS
The intraarterial administration of the product can cause adverse reactions (incoordination, ataxia, muscle weakness), which are fleeting and disappear quickly without the need for medication. This route of administration should be avoided. 
It should not be used together with other nonsteroidal anti-inflammatory drugs. Neither should it be associated with drugs that produce renal toxicity. 
The safety of Flunixin has not been demonstrated when it is administered concomitantly with other medicinal products or biological products. Therefore, if this situation occurs, the patient should be specially controlled. 
The treatment should not exceed 5 days in any of the species for which it is intended.
Do not administer to animals under 3 days. Its use is not advised in pregnant females. Do not administer in race horses during the 8 days prior to the competition. 
Do not mix in the same syringe with other injectable solutions.

RESTRICTIONS OF USE
The time that must elapse between the last day of treatment and the sacrifice of the animal for human consumption is in cattle and swine of 21 days. 
Do not administer the product to dairy cattle if the milk is destined for human consumption. 
The product should not be used in equines intended for human consumption.

FLUNIXIN TECNOFARM

SIDE EFFECTS AND ADVERSE REACTIONS
Occasionally there may be slight inflammatory reaction at the injection site, which resolves favorably in 48-72 hours without the need of any treatment. 
In intramuscular administration it is advisable to divide the dose into two points. Sometimes, after intramuscular administration in cattle, irritation may occur, so intravenous administration is preferable in this species. 
Given the characteristics of the product, the presentation of symptoms of poisoning is very unlikely. 
In the indicated doses, no toxic effects are known. However, at a dose 5 times higher than indicated, adverse effects can be observed. 
There are no specific antidotes.

FLUNIXIN TECNOFARM

DOSIFICATION
Cattle: 
Musculoskeletal conditions: 1 ml per 45 kg of live weight intramuscularly or intravenously; Repeat the dose every 24 hours. 
Mastitis, metritis, respiratory and digestive processes: 2 ml per 45 kg of live weight intravenously. 
Swine: 
In all cases: 2 ml per 45 kg of weight by deep intramuscular route. 
Treatment of the syndrome mastitis? Metritis-agalaxia: the administration should be repeated every 12 hours if the symptoms persist, during 1 to 3 days. 
Digestive processes: repeat every 24 hours. 
Horses:
Musculoskeletal conditions: 1 ml per 45 kg of live weight, intramuscularly or intravenously. If necessary, the treatment can be repeated 24 hours after the first application. The treatment should last 5 days. 
Colic laminitis, shock: 1 ml per 45 kg of live weight, intravenously. The administration should be repeated if the symptoms reappear. In case of laminitis the treatment should last 3 days. 
Digestive and respiratory processes: 1 ml per 45 kg of live weight, intramuscularly or intravenously. Repeat every 24 hours until 5 days.

Leave a Reply

Your email address will not be published. Required fields are marked *